Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
In the latest session, CRISPR Therapeutics AG (NASDAQ: CRSP) closed at $39.04 up 1.77% from its previous closing price of $38.36. In other words, the price has increased by $1.77 from its previous closing price. On the day, 1.73 million shares were traded. CRSP stock price reached its highest trading level at $40.99 during the session, while it also had its lowest trading level at $38.9.
Ratios:
For a deeper understanding of CRISPR Therapeutics AG’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 21.64 and its Current Ratio is at 21.64. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on August 06, 2024, Reiterated its Buy rating but revised its target price to $84 from $88 previously.
On August 02, 2024, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $90.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 02 ’24 when Kulkarni Samarth sold 15,000 shares for $55.10 per share. The transaction valued at 826,564 led to the insider holds 181,540 shares of the business.
Kulkarni Samarth sold 30,000 shares of CRSP for $1,668,678 on Nov 11 ’24. The Chief Executive Officer now owns 196,540 shares after completing the transaction at $55.62 per share. On Oct 14 ’24, another insider, KASINGER JAMES R., who serves as the General Counsel and Secretary of the company, sold 1,089 shares for $46.28 each. As a result, the insider received 50,399 and left with 62,597 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRSP now has a Market Capitalization of 3332200960 and an Enterprise Value of 1624099840. For the stock, the TTM Price-to-Sale (P/S) ratio is 16.43 while its Price-to-Book (P/B) ratio in mrq is 1.72. Its current Enterprise Value per Revenue stands at 8.007 whereas that against EBITDA is -5.188.
Stock Price History:
The Beta on a monthly basis for CRSP is 1.66, which has changed by -0.37094128 over the last 52 weeks, in comparison to a change of 0.22212577 over the same period for the S&P500. Over the past 52 weeks, CRSP has reached a high of $91.10, while it has fallen to a 52-week low of $36.52. The 50-Day Moving Average of the stock is -15.25%, while the 200-Day Moving Average is calculated to be -24.03%.
Shares Statistics:
For the past three months, CRSP has traded an average of 1.75M shares per day and 1853630 over the past ten days. A total of 85.34M shares are outstanding, with a floating share count of 81.68M. Insiders hold about 4.30% of the company’s shares, while institutions hold 69.51% stake in the company. Shares short for CRSP as of 1735603200 were 19097155 with a Short Ratio of 10.93, compared to 1732838400 on 18153184. Therefore, it implies a Short% of Shares Outstanding of 19097155 and a Short% of Float of 25.36.
